Reports Q3 revenue $5.56M, consensus $7.4M. “This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team,” said Todd Nelson and founder of Telesis Bio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TBIO:
- Telesis Bio Reports Third Quarter 2023 Financial Results
- Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
- Telesis Bio announces commercial release of cell-free amplification kit
- Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
- Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
